LAMA2, encoding the α2 subunit of laminin-211 (also known as merosin), is crucial for maintaining the connection between muscle cells and their extracellular environment. Laminin-211 is part of the basement membrane assembly, and its proper function is essential for normal muscle development and function [1,4,6]. Multiple animal models for LAMA2-related dystrophies have been instrumental in advancing the understanding of laminin-211 and its role in the disease [1].

Mutations in the LAMA2 gene lead to LAMA2-related dystrophies (LAMA2-RDs), which include both complete and partial merosin deficiency. Complete merosin deficiency is typically associated with severe congenital muscular dystrophy (CMD), presenting with hypotonia, weakness at birth, joint contractures, and progressive respiratory involvement, while partial merosin deficiency often shows later-onset limb-girdle weakness [1]. LAMA2-RDs also involve the central and peripheral nervous systems, with abnormal white matter on brain MRI and dystrophic muscle on biopsy, along with elevated creatine kinase levels [1]. In addition, epilepsy is a common and sometimes severe feature of LAMA2-RD, and cardiac abnormalities, especially left ventricular systolic dysfunction and arrhythmia, are present in a significant proportion of cases [2,3]. Hypoglycemia is also a risk, especially in non-ambulant patients with a severe phenotype and loss-of-function variants [5].

In conclusion, LAMA2 is essential for normal muscle and nervous system function. The study of LAMA2-related dystrophies using animal models has provided insights into the disease mechanisms, including the role of LAMA2 in muscle and nerve development and function. Understanding LAMA2-related diseases helps in developing potential therapeutic strategies for these often-severe and life-limiting conditions.